Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cholestyramine is a non-absorbable, quaternary ammonium anion-exchange resin used as a lipid-lowering agent and for the management of pruritus associated with partial biliary obstruction. By binding bile acids in the gastrointestinal tract to form an insoluble complex, it prevents their reabsorption and interrupts enterohepatic circulation. This results in an increased fecal loss of bile acids, prompting the liver to compensate by upregulating the conversion of endogenous cholesterol into new bile acids. This process increases the expression of hepatic LDL receptors, leading to a significant reduction in serum low-density lipoprotein (LDL) cholesterol levels. Beyond its primary use in hyperlipidemia, it is frequently employed to treat diarrhea caused by bile acid malabsorption and as an adjunct in the management of digitalis toxicity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cholestyramine.